Background Psychedelic compounds such as lysergic acid diethylamide (LSD), psilocybin,
and 3, 4-Methylenedioxymethamphetamine (MDMA) share a long and complex history with …

In recent years, psychedelic-assisted psychotherapies have reentered the realm of rigorous
scientific inquiry, garnering much attention from both the psychiatric community and the …

Despite resurgent interest in psychedelic-assisted therapy, our insights into psychiatrists'
knowledge and opinions about medicinal psychedelic applications are surprisingly narrow …

Introduction This study explored the current knowledge, attitudes, and clinical practices
regarding psychedelics among mental health professionals in California, where state …

Introduction There is substantial public interest in psychedelics as potential treatments for
psychiatric conditions. However, most psychedelics are criminalized under federal law in the …

Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), or
dimethyltryptamine (DMT), as well as psychoactive drugs that trigger phenomenologically …

Background Numerous clinical trials have supported psychedelic-assisted therapy (PAT) as
a treatment for psychiatric disorders such as depression, anxiety, post-traumatic stress, and …

Psychologists are a vital component of mental health treatment and their perceptions of
psychedelic-assisted therapy are critical for future implementation. This cross-sectional …

Growing evidence from observational studies and clinical trials suggests that psychedelics
such as lysergic acid diethylamide, 3, 4-methylenedioxymethamphetamine, and psilocybin …

Introduction: Psychedelic-assisted psychotherapy is a promising approach in psychiatry;
evidence is growing and it may not be long before mainstream services are expected to offer …